Katalin Podor

Clinical Research Associate @AstraZeneca

Mississauga, ON, CA

Studies: Destiny- L04- An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or MetastaticNSCLC Harboring HER2 Exon 19 or 20 Mutations Neo-Adaura- A Phase Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung CancerMERMAID-2- A Phase Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent TherapyAdaura- A Phase Double-blind, Randomized, Placebo-Controlled Multi-centre, Patients with Epidermal Growth Factor Receptor Mutation Positive Stage Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy Emerald-1-Phase Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

Hawaii Pacific University

courses towards MScN

McMaster University

BScN